Effect of second-generation antiepileptic drugs on diplopia: A meta-analysis of placebo-controlled studies

Abstract

Different antiepileptic drugs (AEDs) may cause similar adverse effects, one of which is diplopia. However, the AEDs causing diplopia and the dose-response effect of each drug remains uncertain. In this study, we compared several second-generation AEDs to find out whether they would contribute to the risk of diplopia and their effect-causing dose. A meta-analysis was performed on 19 studies in agreement with our inclusion criteria. The results showed that eight commonly used second-generation AEDs (gabapentin, levetiracetam, oxcarbazepine, lamotrigine, pregabalin, topiramate, vigabatrin and zonisamide) could cause diplopia. The reported odds ratios (ORs) ranged from 1.406 to 7.996. Ranking risks from the highest to the lowest ORs of the eight AEDs of any dose resulted in the following order: use of oxcarbazepine (7.996), levetiracetam (7.472), lamotrigine (5.258), vigabatrin (3.562), pregabalin (3.048), topiramate (2.660), gabapentin (1.966), zonisamide (1.406). Taking into account the ORs above, we can conclude that second-generation AEDs of any dose may cause diplopia. However, the levetiracetam-caused diplopia needs to be further studied according to the data (OR, 7.472; 95% confidence interval, 0.375–148.772). These findings ask for better concerns about patients’ quality of life when giving antiepileptic treatments.

Keywords

partial seizure / add-on therapy / antiepileptic drugs / diplopia / meta-analysis

References

[1] RopperA.H., BrownR.H.. . Adams and Victor’s principles of neurology, 2005, New York, McGraw-Hill Publishing

[2] BarcsG., WalkerE.B., ElgerC.E., et al.. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia, 2000, 41(12): 1597-1607

[3] BinnieC.D., DebetsR.M.C., EngelsmanM., et al.. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res, 1989, 4(3): 222-229

[4] MatsuoF., BergenD., FaughtE., et al.. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology, 1993, 43(11): 2284-2291

[5] SchapelG.J., BeranR.G., VajdaF.J., et al.. Double-blind, placebo controlled, crossover study of lamotrigine in treatment of resistant partial seizures. J Neurol Neurosurg Psychiatry, 1993, 56(5): 448-453

[6] SmithD., BakerG., DaviesG., et al.. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia, 1993, 34(2): 312-322

[7] MessenheimerJ., RamsayR.E., WillmoreL.J., et al.. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia, 1994, 35(1): 113-121

[8] SchachterS.C., LeppikI.E., MatsuoF., et al.. Lamotrigine: a six-month, placebo-controlled, safety and tolerance study. J Epilepsy, 1995, 8(3): 201-209

[9] FaughtE., WilderB.J., RamsayR.E., et al.. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, 600-mg daily dosages. Neurology, 1996, 46(6): 1684-1690

[10] PriviteraM., FinchamR., PenryJ., et al.. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, 1000-mg daily dosages. Neurology, 1996, 46(6): 1678-1683

[11] The US Gabapentin Study Group No. 5.. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology, 1993, 43(11): 2292-2298

[12] AnhutH., AshmanP., FeuersteinT.J., et al.. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia, 1994, 35(4): 795-801

[13] YamauchiT., KanekoS., YagiK., et al.. Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry Clin Neurosci, 2006, 60(4): 507-515

[14] ArroyoS., AnhutH., KuglerA.R., et al.. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia, 2004, 45(1): 20-27

[15] BeydounA., UthmanB.M., KuglerA.R., et al.. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology, 2005, 64(3): 475-480

[16] ElgerC.E., BrodieM.J., AnhutH., et al.. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia, 2005, 46(12): 1926-1936

[17] BeranR.G., BerkovicS.F., BuchananN., et al.. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure, 1996, 5(4): 259-265

[18] BruniJ., GubermanA., VachonL., et al.. Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. Seizure, 2000, 9(3): 224-232

[19] TsaiJ.J., YenD.J., HsihM.S., et al.. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study. Epilepsia, 2006, 47(1): 72-81

[20] BaulacM., LeppikI.E.. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res, 2007, 75(2–3): 75-83

[21] PorterR.J.. . General principle: how to use antiepileptic drugs, 1989, New York, Raven Press

[22] ReynoldsE.H., ShorvonS.D.. Monotherapy or polytherapy for epilepsy?. Epilepsia, 1981, 22(1): 1-10